Abstract
Androgens are required to maintain the integrity of the prostate and the survival of androgen dependent epithelial cells within the gland. Anti-androgens are the primary treatment strategy for non-localized prostate cancer, but ultimately fail over time with the development of androgen independent tumors. Estrogens affect the growth and development of the prostate and may affect the development of prostate cancer. Because of the side effects of estrogen treatment alternative therapies include the use of phytoestrogens as chemopreventative and chemotherapeutic treatment modalities. Phytoestrogens, can cause growth arrest and in some cases apoptosis in prostate cancer cells in vivo and in vitro. This may be due to the estrogenic properties of the compounds or alternative mechanisms of action. A number of phytoestrogens have been shown to have anti-androgenic effects and anti-oxidant activities. Other mechanisms include inhibition of 5α- reductase, 17β-hydroxysteroid dehydrogenase, aromatase, tyrosine specific protein kinases and DNA topoisomerase II. This review examines the possible relation between phytoestrogens and prostate cancer and their possible use in prostate cancer prevention or management.
Keywords: phytoestrogens, prostate cancer, estrogen receptor, flavonoids, lignans, stilbenes, chemoprevention, chemotherapy
Current Drug Targets
Title: Phytoestrogens and Prostate Cancer
Volume: 4 Issue: 3
Author(s): Colm Morrissey and R. William G. Watson
Affiliation:
Keywords: phytoestrogens, prostate cancer, estrogen receptor, flavonoids, lignans, stilbenes, chemoprevention, chemotherapy
Abstract: Androgens are required to maintain the integrity of the prostate and the survival of androgen dependent epithelial cells within the gland. Anti-androgens are the primary treatment strategy for non-localized prostate cancer, but ultimately fail over time with the development of androgen independent tumors. Estrogens affect the growth and development of the prostate and may affect the development of prostate cancer. Because of the side effects of estrogen treatment alternative therapies include the use of phytoestrogens as chemopreventative and chemotherapeutic treatment modalities. Phytoestrogens, can cause growth arrest and in some cases apoptosis in prostate cancer cells in vivo and in vitro. This may be due to the estrogenic properties of the compounds or alternative mechanisms of action. A number of phytoestrogens have been shown to have anti-androgenic effects and anti-oxidant activities. Other mechanisms include inhibition of 5α- reductase, 17β-hydroxysteroid dehydrogenase, aromatase, tyrosine specific protein kinases and DNA topoisomerase II. This review examines the possible relation between phytoestrogens and prostate cancer and their possible use in prostate cancer prevention or management.
Export Options
About this article
Cite this article as:
Morrissey Colm and G. Watson William R., Phytoestrogens and Prostate Cancer, Current Drug Targets 2003; 4 (3) . https://dx.doi.org/10.2174/1389450033491154
DOI https://dx.doi.org/10.2174/1389450033491154 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Apoptosis-Inducing Activity and Antiproliferative Effect of Gossypin on PC-3 Prostate Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Targeting Hsp90 in Non-Cancerous Maladies
Current Topics in Medicinal Chemistry Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes
Current Genomics HIV: A Raft-Targeting Approach for Prevention and Therapy Using Plant-Derived Compounds (Review)
Current Drug Targets Possible Binding Mode Analysis of Pyrazolo-triazole Hybrids as Potential Anticancer Agents through Validated Molecular Docking and 3D-QSAR Modeling Approaches
Letters in Drug Design & Discovery Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
Current Neuropharmacology Multiligand Endocytosis and Congenital Defects: Roles of Cubilin, Megalin and Amnionless
Current Pharmaceutical Design Taxotere Chemosensitivity Evaluation in Rat Breast Tumor by Multimodal Imaging: Quantitative Measurement by Fusion of MRI, PET Imaging with MALDI and Histology
Recent Patents on Medical Imaging Peptide Self-Assemblies for Drug Delivery
Current Topics in Medicinal Chemistry Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with <sup>177</sup>Lu and Conjugated to Peptides
Current Radiopharmaceuticals Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer
Current Medicinal Chemistry Molecular Chaperone ORP150 in ER Stress–related Diseases
Current Pharmaceutical Design Receptor-Based Design of Cytokine Therapeutics
Current Pharmaceutical Biotechnology Bone Seeking Radiopharmaceuticals for Palliation of Pain in Cancer Patients with Osseous Metastases
Anti-Cancer Agents in Medicinal Chemistry Chromogranin A as a Calcium-Binding Precursor for a Multitude of Regulatory Peptides for the Immune, Endocrine and Metabolic Systems
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Organoids: Current Implications and Pharmaceutical Applications in Liver Diseases
Current Molecular Pharmacology PDE5 Inhibitors Offer Novel Mechanisms in Combination and Solo Cancer Therapy
Current Cancer Therapy Reviews Relationships Between the Structural Properties of Flavonoids and their Inhibitory Activities Against Matrix Metallopeptidase 9
Letters in Drug Design & Discovery Altered Glycosylation of Proteins in Cancer: What Is the Potential for New Anti-Tumour Strategies
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Antitumor Activity of Novel N-Benzoyl-N'-substituted Pyrimidinyl (Thio)semicarbazide Derivatives
Letters in Drug Design & Discovery